SCHEMBL2067701

SCHEMBL2067701

NCc1cc(Br)cnc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
LOXL2 Q9Y4K0 2/20 0.35
CCR5 P51681 1/20 0.33
DYRK1A Q13627 4/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CHEK1 O14757 1/20 0.32
AURKA O14965 1/20 0.32
DAPK3 O43293 1/20 0.32
JAK2 O60674 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
ABL1 P00519 1/20 0.32
CSF1R P07333 1/20 0.32
RET P07949 1/20 0.32
IGF1R P08069 1/20 0.32
FGFR1 P11362 1/20 0.32
PDGFRA P16234 1/20 0.32
PRKACA P17612 1/20 0.32
FLT1 P17948 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067183 0.84 TAAR1 (0.37) HTTKMT2A
SCHEMBL19759439 0.79 SMN1; SMN2 (0.35) HTTKMT2ADYRK1ASMN1; SMN2AURKA
SCHEMBL4541092 0.79 OPRK1 (0.39) HTTKMT2ADYRK1ASMN1; SMN2PLAU
SCHEMBL29054010 0.79 HTT (0.34) HTTKMT2ADYRK1ASMN1; SMN2PLAU
SCHEMBL26041676 0.78 HTT (0.33) HTTKMT2ASMN1; SMN2PLAU
SCHEMBL29607382 0.77 HTT (0.56) HTTKMT2ACCR5DYRK1ASMN1; SMN2
SCHEMBL14051242 0.77 HTT (0.56) HTTKMT2ACCR5DYRK1ASMN1; SMN2
SCHEMBL15923198 0.76 KMT2A (0.32) HTTKMT2ASMN1; SMN2IDO1
SCHEMBL15052641 0.75 CCR5 (0.42) HTTKMT2ALOXL2CCR5DYRK1A
SCHEMBL2066694 0.75 HTT (0.39) HTTKMT2ACCR5DYRK1ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 HTT 1605/4885KMT2A 1019/4885LOXL2 4185/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 HTT 1605/4885KMT2A 1019/4885LOXL2 4185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.